This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study for Prevention of Kidney Disease in Diabetic Patients (BENEDICT) (BENEDICT)

This study has been completed.
Information provided by:
Abbott Identifier:
First received: September 13, 2005
Last updated: July 11, 2008
Last verified: June 2008
The BENEDICT study is conducted to examine the effects of an ACE inhibitor, calcium channel blockade, a combination of these, and placebo, in the prevention of micro- and macro-albuminuria in Type 2 diabetic patients.

Condition Intervention Phase
Hypertension Diabetes Drug: trandolapril Drug: trandolapril/verapamil Drug: placebo Drug: verapamil Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT)

Resource links provided by NLM:

Further study details as provided by Abbott:

Primary Outcome Measures:
  • Phase A: microalbuminuria; Phase B: progression from microalbuminuria to macroalbuminuria. [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Course of albumin excretion over time, GFR, blood pressure (BP), incidence of major CV events, overall and CV mortality, HbA1c, progression of retinal changes. [ Time Frame: 3 years ]

Enrollment: 1204
Study Start Date: March 1997
Primary Completion Date: January 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: A-1, B-1
A-1 pertains to Phase 1; B-1 pertains to Phase 2
Drug: trandolapril
2 mg QD
Other Names:
  • ABT-878
  • Mavik/Gopten
Active Comparator: A-2, B-2
A2 pertains to Phase 1; B-2 pertains to Phase 2
Drug: trandolapril/verapamil
180/2 mg QD
Other Names:
  • VeraTran
  • Tarka
Placebo Comparator: A-3 Drug: placebo
1 tablet QD
Active Comparator: A-4 Drug: verapamil
SR 240 mg QD
Other Name: ABT-150


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 Diabetes
  • Hypertension

Exclusion Criteria:

  • Albuminuria (Phase A)
  • Non-diabetic renal disease
  • Subject has a hypersensitivity to ACE inhibitor, CCB
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00235014

Sponsors and Collaborators
Study Director: Global Medical Information 1-800-633-9110 Abbott
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Udo Legler, MD, Abbott Identifier: NCT00235014     History of Changes
Other Study ID Numbers: VeraTran 083
Study First Received: September 13, 2005
Last Updated: July 11, 2008

Keywords provided by Abbott:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Anti-Arrhythmia Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Antihypertensive Agents processed this record on August 22, 2017